SCHEMBL43836

SCHEMBL43836

CCCCCCCCCCCCCCCCOC(=O)CC(O)(CC(=O)O)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.53
ALDH1A1 P00352 1/20 0.48
RAD52 P43351 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
FAAH O00519 1/20 0.45
DGKA P23743 1/20 0.44
HTR2C P28335 1/20 0.44
HCAR2 Q8TDS4 1/20 0.42
EPHX1 P07099 1/20 0.42
S1PR4 O95977 1/20 0.42
S1PR1 P21453 1/20 0.42
S1PR3 Q99500 1/20 0.42
S1PR5 Q9H228 1/20 0.42
HSPD1 P10809 1/20 0.42
BLM P54132 1/20 0.42
HSPE1 P61604 1/20 0.42
TSHR P16473 1/20 0.41
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320757 1.00 NAAA (0.53) NAAAALDH1A1RAD52NPSR1FAAH
SCHEMBL31397812 1.00 NAAA (0.53) NAAAALDH1A1RAD52NPSR1FAAH
SCHEMBL1400504 1.00 NAAA (0.53) NAAAALDH1A1RAD52NPSR1FAAH
SCHEMBL42510 1.00 NAAA (0.53) NAAAALDH1A1RAD52NPSR1FAAH
SCHEMBL2145409 1.00 NAAA (0.53) NAAAALDH1A1RAD52NPSR1FAAH
SCHEMBL9410612 1.00 NAAA (0.53) NAAAALDH1A1RAD52NPSR1FAAH
SCHEMBL17812796 1.00 NAAA (0.53) NAAAALDH1A1RAD52NPSR1FAAH
SCHEMBL4598009 1.00 NAAA (0.53) NAAAALDH1A1RAD52NPSR1FAAH
SCHEMBL17812513 1.00 NAAA (0.53) NAAAALDH1A1RAD52NPSR1FAAH
SCHEMBL31632218 1.00 NAAA (0.53) NAAAALDH1A1RAD52NPSR1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 842 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118986778-B Composition, preparation and application of 4-butylresorcinol nanoliposome 杭州皓阳生物技术有限公司 2025-02-25 CN claimed
CN-118986778-A Composition, preparation and application of 4-butylresorcinol nanoliposome 杭州皓阳生物技术有限公司 2024-11-22 CN claimed
CN-118703274-A Laundry gel bead composition with hydroxyl crosslinking function and preparation method and application thereof 广州凡岛网络科技有限公司 2024-09-27 CN claimed
CN-114315576-B Preparation method of bio-based degradable plasticizer 山东万图高分子材料股份有限公司 2024-08-20 CN claimed
EP-3810135-A1 ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS Poviva Corp. (US) 2021-04-28 EP claimed
EP-3781163-A1 COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF Poviva Corp. (US) 2021-02-24 EP claimed
US-20210045998-A1 TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS Poviva Corp. 2021-02-18 US claimed
CN-112011413-A Multi-surface cleaning agent containing sodium cumene sulfonate and modified surfactant 上海毅诺生物科技有限公司 2020-12-01 CN claimed
WO-2019202396-A1 COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOF POVIVA TEA, LLC (US) 2019-10-24 WO claimed
CN-109091417-A Anti-oxidant sun-proof liquid blush of one kind and preparation method thereof 吴静 2018-12-28 CN claimed
US-20080019860-A1 LIQUID MONOPHASIC LIPID-SOLUBLE ANTIOXIDANT COMPOSITIONS AND PROCESSES FOR MAKING THE COMPOSITIONS NOVUS INTERNATIONAL INC. (US) 2008-01-24 US claimed
WO-2007062304-A2 BIODIESEL FUEL COMPOSITIONS HAVING INCREASED OXIDATIVE STABILITY NOVUS INTERNATIONAL, INC. (US) 2007-05-31 WO claimed
US-20070113467-A1 BIODIESEL FUEL COMPOSITIONS HAVING INCREASED OXIDATIVE STABILITY NOVUS INTERNATIONAL INC. (US) 2007-05-24 US claimed
US-20040180021-A1 Composition comprising at least one film-forming polymer L'OREAL S.A. (FR) 2004-09-16 US claimed
EP-1009398-A4 MOLECULAR COMPLEX AND CONTROL-RELEASE OF ALPHA HYDROXYACIDS YU RUEY J (US) 2004-06-23 EP claimed
EP-1428494-A1 Mascara comprising filmbuilding polymer and fatty phase L'OREAL (FR) 2004-06-16 EP claimed
WO-2004041220-A2 COMPOSITION CONTAINING A SEMI-CRYSTALLINE POLYMER AND A PASTY FATTY SUBSTANCE L'OREAL (FR) 2004-05-21 WO claimed
EP-1009398-A1 MOLECULAR COMPLEX AND CONTROL-RELEASE OF ALPHA HYDROXYACIDS Yu, Ruey J., Dr. (US) 2000-06-21 EP claimed
US-5877212-A HYDROGEN BONDING WITH COMPLEXING AGENT YU RUEY J (US) 1999-03-02 US claimed
WO-1998046217-A1 MOLECULAR COMPLEX AND CONTROL-RELEASE OF ALPHA HYDROXYACIDS YU RUEY J (US) 1998-10-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210045998-A1 TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS LIPA, MMP8, MMP1 NAAA 1359/4885ALDH1A1 2693/4885RAD52 3052/4885
US-20040180021-A1 Composition comprising at least one film-forming polymer KRT18, CUTA, DSG1 NAAA 3307/4885ALDH1A1 2315/4885RAD52 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.